Skip to main content
Premium Trial:

Request an Annual Quote

French Scanner Vendor Innopsys Establishes US Subsidiary, Plans Higher-Resolution Platform


This story was originally posted on Nov. 4.

By Justin Petrone

Innopsys, a Carbonne, France-based optics company that makes and sells high-resolution microarray scanners, recently established a US presence. The move comes as the firm prepares to launch a high-resolution scanner next year.

The new office, based in Chicago, will mainly serve as a sales and marketing hub as Innopsys looks to grow its US customer base. The company to date has relied on a distributor, Sunnyvale, Calif.-based Arrayit, to cover the US.

According to CEO Stéphane Le Brun, Innopsys has "been doing well in Europe and Asia, but would like to increase sales" in the US. "The idea is to offer direct support to US users," he said. "We also want to have feedback from the US market for product development purposes." He added that Innopsys will continue to work with Arrayit in the US market.

Le Brun spoke with BioArray News during the American Society of Human Genetics annual meeting, held in Washington, DC, last week.

Founded in 1999, Innopsys entered the biotechnology market in 2006 with its InnoScan 710, a 3-micron resolution system. In 2008, it launched its InnoScan 900, a 1-micron resolution system (BAN 6/3/2008). The firm also sells an autoloader and Mapix software for use with its scanners.

The need for higher-resolution scanners has been driven by the availability of the higher-density microarrays sold by firms like Agilent Technologies and Roche NimbleGen. Rivals in the scanner market, such as Tecan and Molecular Devices, have also upgraded their systems in recent years (BAN 5/13/2008).

According to Le Brun, the company is now planning an even higher resolution scanner, one capable of 0.25 micron level resolution. This new system should be available by the end of 2011, Le Brun said. Given its high-resolution capabilities, Le Brun said the new platform will be "geared more toward imaging tissue arrays" than the current generation of high-density chips sold on the market.

Have topics you'd like to see covered in BioArray News? Contact the editor at jpetrone [at] genomeweb [dot] com

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.